Ecoslops SA. Ecoslops SA is a France-based company principally engaged in the converting pertroleum residues from shipping (slops and sludge) in new marine fuels recycled. The Company offers seaports, residues collectors, ship-owners and bunker suppliers with a technology to recycle oily waste of ships. Ecoslops SA is active in promoting the development of the P2R unit by its incorporation in a more global plant: Oil Waste Processing Plant (OW2P). The OW2P technology combines a refining petroleum process (P2R) with appropriate clean water. The Company recycles the waste in order to be used in electricity production and steam production among others. The Company's fuel production is located in the port of Sines, Portugal.

Inventiva is a clinical stage biotechnology research company delivering therapies in the areas of oncology, fibrosis and rare diseases. The most advanced clinical programs (IVA337 for systemic sclerosis in Non-Alcoholic Steato-Hepatitis and IVA336 for Maroteaux-Lamy syndrome-MPS VI) have demonstrated efficacy in relevant in vivo and in vitro models as well as safety in phase I and phase II clinical trials. Using its in-house drug discovery platform, which covers target validation, screening, chemistry, ADME and pharmacology, Co. is developing an internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets and nuclear receptors.

ORPEA is a dependency, physical and psychiatric care group based in France. Co. operates long-term and short-term care facilities, including medical care facilities, medical and social care facilities and residential facilities for the elderly. Co. provides short, medium and long-term global physical and mental dependency care. Co. also operates residential facilities for disabled people of any age, hotels, and hotel-related, as well as leisure accommodation facilities. Co. operates in France and abroad (Belgium, Italy, Spain and Switzerland) in three business segments: Long-term care facilities (nursing homes); Post-acute and Rehabilitation care facilities; and Psychiatric care facilities.

Ose Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company principally engaged in the clinical stage biotechnological sector. The Company develops immunotherapy products against invasive or metastatic late-stage cancers. The Company offers a technology, called Memopi, which helps the immune system to eliminate malignant cells; it re-educates the body's immunological memory so that the immune system (and particularly T cytotoxic cells) attacks tumor cells by increasing the patient's specific cytotoxic T response against their cancer. The Company's main product, Texopi, is a patented combination of ten epitopes, selected and optimized from five tumor associated antigens.

Solutions 30 SE is a France-based company that specializes in information technology (IT) repair services for individual and business clients. Its activity is divided into five key fields, such as IT-Telecom, Energy, Audiovisual, Piont of services and Security. Solutions 30 SE has a network of locally based teams throughout France that provide on-site IT assistance either at home or in the workplace. The Company is also present in Italy. Solutions 30 SE operates through Telima Mediterranee, Telima Ile de France, Mulot Assistance, Telima Reims Family, Telima Mediterranee Family, Mixnet, B&F GmbH in Germany, Connecting Cable GmbH and Vodafone Kabel Deutschland Field Services Gmbh, among others.

SQLI SA is a France-based company that specializes in the design and creation of Information Technology (IT) systems. The Company specializes in implementing information systems based on new technologies. It operates in Business Information Systems sector, Digital Enterprise sector, E-commerce division, Communication and Organisation and management divisions. SQLI SA works with its clients from the consulting stage, through the design and installation processes, to the training and monitoring phase. The Company operates a network of offices in France, Benelux, Switzerland, Morocco and Canada, among others. It operates through brands: Wax Interactive and SQLI Enterprise. The Company has such subsidiaries as LSF Interactive, digital agency of marketing and communication, InventCommerce Ltd, a London-based Internet service provider and Star Republic, among others.

Valneva, together with its subsidiaries, is focused on vaccine development and antibody discovery. Co. generates revenue from both its marketed product, a vaccine for the prevention of Japanese encephalitis (IXIARO®/JESPECT®), commercial partnerships around a portfolio of product candidates and licensed technology platforms (EB66® cell line, VIVA,Screen antibody discovery technology, and the IC31® adjuvant) developed by Co. Related business activities include product research and development, regulatory and clinical activities, manufacturing of commercial product and advanced clinical product candidates, as well as administrative, corporate development, and marketing and sales activities.